NCT07014930View on ClinicalTrials.gov

Identification of New Tools for Predicting Natural Metabolic Performance of the Liver

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 5, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

January 31, 2026

Conditions
Healthy Volunteers
Interventions
DRUG

Control session

Plasma and urine sampling as well as the determination of the blood OH-omeprazole/omeprazole ratio at baseline by capillary blood sampling.

DRUG

Inhibition session

Plasma and urine sampling as well as the determination of the blood OH-omeprazole/omeprazole ratio at baseline by capillary blood sampling, with prior administration of 50 mg of fluvoxamine for 7 consecutive days (CYP2C19 inhibitor).

DRUG

Induction session

Plasma and urine sampling as well as the determination of the blood OH-omeprazole/omeprazole ratio at baseline by capillary blood sampling, with prior administration of 600 mg of rifampicin for 10 consecutive days (CYP2C19 inducer).

Trial Locations (1)

1211

RECRUITING

The Geneva University Hospitals (HUG), Geneva

All Listed Sponsors
collaborator

Fonds national Suisse

UNKNOWN

lead

Caroline Samer

OTHER